Biodefense Market Research Report Information by Disease Type (Anthrax, Smallpox, Botulism, Influenza, Radiation/Nuclear, And Others) by Treatment (Vaccination, And Medication), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING GOVERNMENT INITIATIVES AND FUNDING

4.2.2 RISE IN DEMAND FOR VACCINES

4.3 RESTRAINTS

4.3.1 LOW MARKET PENETRATION IN DEVELOPING AND UNDERDEVELOPED COUNTRIES

4.4 OPPORTUNITIES

4.4.1 TECHNOLOGICAL ADVANCEMENT

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D & DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL BIODEFENSE MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON PRODUCTION

5.3.3 IMPACT ON REGIONS

5.3.4 IMPACT ON PRICING

5.4 AUTHORITIES BUDGET AND FINANCING PROGRAMS FOR BIODEFENSE BY REGION

6 GLOBAL BIODEFENSE MARKET, BY DISEASE TYPE

6.1 OVERVIEW

6.2 ANTHRAX

6.3 SMALL POX

6.4 BOTULISM

6.5 INFLUENZA

6.6 RADIATION/NUCLEAR

6.7 OTHERS

7 GLOBAL BIODEFENSE MARKET, BY TREATMENT

7.1 OVERVIEW

7.2 VACCINATION

7.3 MEDICATION

8 GLOBAL BIODEFENSE MARKET, BY REGION

8.1 GLOBAL OVERVIEW

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 GERMANY

8.3.2 UK

8.3.3 FRANCE

8.3.4 ITALY

8.3.5 SPAIN

8.3.6 REST OF EUROPE

8.4 ASIA-PACIFIC

8.4.1 JAPAN

8.4.2 INDIA

8.4.3 SOUTH KOREA

8.4.4 AUSTRALIA

8.4.5 REST OF ASIA-PACIFIC

8.5 REST OF THE WORLD

8.5.1 MIDDLE EAST

8.5.2 AFRICA

8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN GLOBAL BIODEFENSE MARKET

9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BIODEFENSE MARKET

9.5 KEY DEVELOPMENT ANALYSIS

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL

9.6.2 PARTNERSHIP/COLLABORATION/AGREEMENT

9.6.3 ACQUISITION/EXPANSION/INVESTMENT

9.7 MAJOR PLAYERS FINANCIAL

9.7.1 SALES, 2023

9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2023

10 COMPANY PROFILE

10.1 EMERGENT

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 BAVARIAN NORDIC

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 ALTIMMUNE

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 DYNAVAX TECHNOLOGIES

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 KEY STRATEGIES

10.5 SIGA TECHNOLOGIES

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 SWOT ANALYSIS

10.5.6 KEY STRATEGIES

10.6 ELUSYS THERAPEUTICS, INC.

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL OVERVIEW

10.6.3 PRODUCTS OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 KEY STRATEGIES

10.7 FABENTECH BIOTECH

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 SWOT ANALYSIS

10.7.6 KEY STRATEGIES

10.8 CLEVELAND BIOLABS, INC.

10.8.1 COMPANY OVERVIEWS

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 KEY STRATEGIES

10.9 OLOGY BIOSERVICES, INC.

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 KEY STRATEGIES

10.10 NOVAVAX, INC.

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 PRODUCTS OFFERED

10.10.4 KEY DEVELOPMENTS

10.10.5 SWOT ANALYSIS

10.10.6 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 BIODEFENSE BUDGET, BY REGION, 2023 (USD MILLION)

TABLE 3 GLOBAL BIODEFENSE MARKET, 2019–2032 (USD MILLION)

TABLE 4 GLOBAL BIODEFENSE MARKET, BY REGION, 2019-2032 (USD MILLION)

TABLE 5 NORTH AMERICA: BIODEFENSE MARKET, BY COUNTRY, 2019-2032 (USD MILLION)

TABLE 6 NORTH AMERICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 7 NORTH AMERICA: BIODEFENSE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 8 NORTH AMERICA: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE 2019-2032 (USD MILLION)

TABLE 9 US: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 10 US: BIODEFENSE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 11 US: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE,2019-2032 (USD MILLION)

TABLE 12 CANADA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 13 CANADA: BIODEFENSE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 14 CANADA: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 15 EUROPE: BIODEFENSE MARKET, BY COUNTRY, 2019-2032 (USD MILLION)

TABLE 16 EUROPE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 17 EUROPE: BIODEFENSE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 18 EUROPE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 19 GERMANY: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 20 GERMANY: BIODEFENSE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 21 GERMANY: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 22 UK: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 23 UK: BIODEFENSE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 24 UK: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 25 FRANCE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 26 FRANCE: BIODEFENSE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 27 FRANCE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 28 ITALY: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 29 ITALY: BIODEFENSE MARKET, BY TREATMENT, 2019–2032 (USD MILLION)

TABLE 30 ITALY: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 31 SPAIN: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 32 SPAIN: BIODEFENSE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 33 SPAIN: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 34 REST OF EUROPE: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 35 REST OF EUROPE: BIODEFENSE MARKET, BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 36 REST OF EUROPE: BIODEFENSE MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 37 ASIA-PACIFIC: BIODEFENSE MARKET, BY COUNTRY, 2019-2032 (USD MILLION)

TABLE 38 ASIA-PACIFIC: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 39 ASIA-PACIFIC: BIODEFENSE MARKET BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 40 ASIA-PACIFIC: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 41 JAPAN: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 42 JAPAN: BIODEFENSE MARKET BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 43 JAPAN: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 44 INDIA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 45 INDIA: BIODEFENSE MARKET BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 46 INDIA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 47 SOUTH KOREA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 48 SOUTH KOREA: BIODEFENSE MARKET BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 49 SOUTH KOREA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 50 AUSTRALIA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 51 AUSTRALIA: BIODEFENSE MARKET BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 52 AUSTRALIA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 53 REST OF ASIA-PACIFIC: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 54 REST OF ASIA-PACIFIC: BIODEFENSE MARKET BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 55 REST OF ASIA-PACIFIC: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 56 REST OF THE WORLD: BIODEFENSE MARKET, BY COUNTRY, 2019-2032 (USD MILLION)

TABLE 57 REST OF THE WORLD: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 58 REST OF THE WORLD: BIODEFENSE MARKET BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 59 REST OF THE WORLD: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 60 MIDDLE EAST: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 61 MIDDLE EAST: BIODEFENSE MARKET BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 62 MIDDLE EAST: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 63 AFRICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 64 AFRICA: BIODEFENSE MARKET BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 65 AFRICA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 66 LATIN AMERICA: BIODEFENSE MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION)

TABLE 67 LATIN AMERICA: BIODEFENSE MARKET BY TREATMENT, 2019-2032 (USD MILLION)

TABLE 68 LATIN AMERICA: BIODEFENSE MARKET FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)

TABLE 69 MAJOR PLAYERS IN GLOBAL BIODEFENSE MARKET

TABLE 1 MOST ACTIVE PLAYER IN GLOBAL BIODEFENSE MARKET

TABLE 2 PRODUCT LAUNCH/ PRODUCT APPROVAL

TABLE 3 PARTNERSHIP/ COLLABORATION /AGREEMENT

TABLE 4 ACQUISITION/EXPANSION/INVESTMENT

TABLE 5 EMERGENT: PRODUCTS OFFERED

TABLE 6 EMERGENT: KEY DEVELOPMENTS

TABLE 7 BAVARIAN NORDIC: PRODUCTS OFFERED

TABLE 8 BAVARIAN NORDIC: KEY DEVELOPMENTS

TABLE 9 ALTIMMUNE: PRODUCTS OFFERED

TABLE 10 DYNAVAX TECHNOLOGIES: PRODUCTS OFFERED

TABLE 11 DYNAVAX TECHNOLOGIES: KEY DEVELOPMENTS

TABLE 12 SIGA TECHNOLOGIES: PRODUCTS OFFERED

TABLE 13 SIGA TECHNOLOGIES: KEY DEVELOPMENTS

TABLE 14 ELUSYS THERAPEUTICS, INC.: PRODUCTS OFFERED

TABLE 15 ELUSYS THERAPEUTICS, INC.: KEY DEVELOPMENTS

TABLE 16 FABENTECH BIOTECH: PRODUCTS OFFERED

TABLE 17 FABENTECH BIOTECH: KEY DEVELOPMENTS

TABLE 18 CLEVELAND BIOLABS, INC.: PRODUCTS OFFERED

TABLE 19 OLOGY BIOSERVICES, INC.: PRODUCTS OFFERED

TABLE 20 OLOGY BIOSERVICES, INC.: KEY DEVELOPMENTS

TABLE 21 NOVAVAX, INC.: PRODUCTS OFFERED

TABLE 22 NOVAVAX, INC.: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 GLOBAL BIODEFENSE MARKET STRUCTURE

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 3 MARKET DYNAMICS: GLOBAL BIODEFENSE MARKET

FIGURE 4 DRIVER IMPACT ANALYSIS

FIGURE 5 RESTRAINT IMPACT ANALYSIS

FIGURE 6 VALUE CHAIN ANALYSIS: GLOBAL BIODEFENSE MARKET

FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL BIODEFENSE MARKET

FIGURE 8 GLOBAL BIODEFENSE MARKET; DISEASE TYPE SEGMENT ATTRACTIVENESS, (USD MILLION)

FIGURE 9 GLOBAL BIODEFENSE MARKET; TREATMENT SEGMENT ATTRACTIVENESS, (USD MILLION)

FIGURE 10 GLOBAL BIODEFENSE MARKET SHARE, BY REGION, 2023 (% SHARE)

FIGURE 11 GLOBAL BIODEFENSE MARKET, BY REGION, 2023 & 2032 (USD MILLION)

FIGURE 12 NORTH AMERICA MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2023(USD MILLION)

FIGURE 13 NORTH AMERICA: BIODEFENSE MARKET SHARE, BY COUNTRY, 2023 (% SHARE)

FIGURE 14 NORTH AMERICA: BIODEFENSE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)

FIGURE 15 EUROPE MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2023(USD MILLION)

FIGURE 16 EUROPE: BIODEFENSE MARKET SHARE, BY COUNTRY, 2023 (% SHARE)

FIGURE 17 EUROPE: BIODEFENSE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)

FIGURE 18 ASIA-PACIFIC MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2032 (USD MILLION)

FIGURE 19 ASIA-PACIFIC: BIODEFENSE MARKET, BY COUNTRY, 2019 & 2032 (USD MILLION)

FIGURE 20 ASIA-PACIFIC: BIODEFENSE MARKET SHARE (%), BY COUNTRY, 2023

FIGURE 21 REST OF THE WORLD MARKET ANALYSIS: BIODEFENSE MARKET, 2019-2032 (USD MILLION)

FIGURE 22 REST OT THE WORLD: BIODEFENSE MARKET, BY REGION, 2019 & 2032 (USD MILLION)

FIGURE 23 REST OF THE WORLD: BIODEFENSE MARKET SHARE (%), BY COUNTRY, 2023

FIGURE 24 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 25 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL BIODEFENSE MARKET

FIGURE 26 GLOBAL BIODEFENSE MARKET: COMPETITIVE LANDSCAPE

FIGURE 27 MAJOR PLAYERS SALES, 2023

FIGURE 28 MAJOR PLAYERS R&D EXPENDITURE, 2023

FIGURE 29 EMERGENT: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 EMERGENT: SWOT ANALYSIS

FIGURE 31 BAVARIAN NORDIC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 BAVARIAN NORDIC: SWOT ANALYSIS

FIGURE 33 ALTIMMUNE: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 DYNAVAX TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 SIGA TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 36 SIGA TECHNOLOGIES: SWOT ANALYSIS

FIGURE 37 FABENTECH BIOTECH: SWOT ANALYSIS

FIGURE 38 CLEVELAND BIOLABS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 39 NOVAVAX, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 40 NOVAVAX, INC.: SWOT ANALYSIS